Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_assertion type Assertion NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_head.
- NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_assertion description "[We identified RAS mutations in 16 out of 57 (28.1%) FAs, 2 out of 8 (25%) NWDTCs, 8 out of 42 (19.0%) FVPTCs, 2 out of 10 (20.0%) FTCs, 1 out of 12 (8.3%) Hurthle cell variants of FA, 3 out of 46 (6.5%) goiters, 1 out of 18 (5.6%) hyperplastic nodules, 3 out of 56 (5.4%) micro PTCs, 2 out of 115 (1.7%) PTCs, 0 out of 7 (0%) Hurthle cell variants of FTC, and 0 out of 10 (0%) HT lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_provenance.
- NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_assertion evidence source_evidence_literature NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_provenance.
- NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_assertion SIO_000772 24222113 NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_provenance.
- NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_assertion wasDerivedFrom befree-20150227 NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_provenance.
- NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_assertion wasGeneratedBy ECO_0000203 NP652952.RAc35r5Na1Fv4N35zAa2uaxG-7w-h2NFR68zWqOyLAruQ130_provenance.